Bond of somatostatin analogues of cantharidin liposomes and in hyperbaric oxygen treatment and assessment for breast cancer
Evaluation of Octreotide-Conjugated Liposomal Cantharidin in Hyperbaric Oxygen Environment Treating for Breast Cancer
Abstract
Liposomes used in cancer chemotherapy, there are many studies, and a small number of listed products. Therefore, a target of chemotherapy drugs liposomal formulation still worth studying.
In this study, the design of targeted liposomes and the surface bonding
somatostatin analogues, Octreotide, and the specific use of their tumor cells have specific binding properties, and cause endocytosis, increasing drugs Jinru tumor, increasing drug effect.
When hyperbaric oxygen causes vessels and cell proliferation to tumor blood flow, so that the drugs reach the tumor increased. When the cells activated by the stimulation of oxygen, drugs to increase endocytosis. When hyperbaric oxygen demonstrated inhibition of breast cancer cells, angiogenesis, we also considered the effect of chemotherapy drugs.
Cantharidin in cancer cells in the experiment are obvious features. Used in
animal experiments, however, face a high dose of lethal trade, low doses of invalid issues. Thus, in animal experiments, the cantharidin coated liposomes, easily overcome the problem of death, and found significantly reduced tumor volume.
"Hyperbaric oxygen" and "Octreotide bond liposomes", which is to increase the cytotoxicity of cantharidin.
Liposomes formula of cantharidin cantharidin in vivo to overcome the toxicity and significantly reduced tumor volume.
English Abstract
